Gyre Therapeutics GYRE 深 沪
等待开盘 10-31 09:30:00 美东时间
4.555
-1.855
-28.94%
华盛通- 最 高6.30
- 今 开6.27
- 成交量 39.41万股
- 最 低 4.515
- 昨 收 6.41
- 总市值 4.83亿
- 52周最高 9.14
- 市盈率 静 202.44
- 换手率 0.37%
- 52周最低 4.515
- 委 比 24.55%
- 总股本 1.06亿
- 历史最高 4834.95
- 量 比 2.89
- 振 幅 27.85%
- 历史最低 -19.80
- 每 手 1
- 风险率 0.75%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gyre Therapeutics to Participate in Upcoming September Investor Conferences
Gyre Therapeutics will participate in two healthcare conferences in September 2026: the Cantor Global Healthcare Conference on September 9 and the Morgan Stanley Healthcare Conference on September 16. Both events will feature fireside chats available via webcast. Gyre, a biopharmaceutical company, focuses on developing small-molecule therapeutics for organ fibrosis and inflammatory diseases. Its subsidiary, Cullgen Inc., specializes in targeted p...
09-03 11:00
Gyre Therapeutics Highlights Capital-Efficient Global Development Strategy
Gyre Therapeutics ( ($GYRE) ) just unveiled an announcement. On September 1, 20...
09-01 21:35
Gyre Therapeutics unveils capital-efficient global development strategy
An update from Gyre Therapeutics ( ($GYRE) ) is now available. On August 26, 20...
08-26 21:28
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $102.300M Est
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $102.300 million estimate.
08-07 20:00
Gyre Therapeutics Q2 EPS $(0.12) Misses $(0.04) Estimate, Sales $29.105M Beat $26.490M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.12) per share which missed the analyst consensus estimate of $(0.04) by 200 percent. The company reported quarterly sales of $29.105 million which beat the analyst consensus estimate of $26.490 million by 9.87 percent. This is a 8.72 p...
08-07 19:39
Gyre Therapeutics shares are trading lower after the company reported worse-than-expected Q1 sales results.
Gyre Therapeutics shares are trading lower after the company reported worse-tha...
05-08 00:23
Gyre Therapeutics Affirms FY2026 Sales Guidance of $100.500M-$111.000M vs $137.033M Est
Gyre Therapeutics (NASDAQ:GYRE) affirms FY2026 sales outlook from $100.500 million-$111.000 million to $100.500 million-$111.000 million vs $137.033 million estimate.
05-07 20:39
Gyre Therapeutics Q1 Adj. EPS $(0.04) Beats $(0.07) Estimate, Sales $22.519M Miss $31.607M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. The company reported quarterly sales of $22.519 million which missed
05-07 18:21
